Table 3 : Percentages and odd ratios for treatment success at 6 months compared to baseline according to the type of treatment and patients' characteristics.

n patients(%) OR for succes at 6 months Treatment modality	Treatment first 3 steps n=87/142 (61.3%)	Treatment 4th and further steps n=55/142 (38.7%)	Overall treatment steps	Odds ratio	Standard error	95%	CI	p value	Abbre viation s: CI = confid ence interva l; GCS
Systemic GCS	111/132 (84%)	7/10 (70%)	118/142 (83%)	2.733	0.924	1.408	5.305	0.003	= glucoc
Injected GCS	20/29 (83%)	8/9 (89%)	32/38 (84%)	4.194	1.635	1.953	9.007	< 0.001	orticos teroids
Antimetabolites	36/60 (60%)	7/13 (54%)	43/73 (59%)	1.980	0.655	1.034	3.790	0.039	; IVIg =
Anti-TNF	8/19 (42%)	3/9 (33%)	11/28 (39%)	1.046	0.449	0.450	2.429	0.916	intrave nous
Ciclosporin	25/35 (71%)	2/6 (33%)	27/41 (66%)	2.587	0.956	1.253	5.340	0.010	immun oglobu
IVIg	8/15 (53%)	0/1	8/16 (50%)	1.274	0.613	0.495	3.276	0.614	lins.
Interferon	27/31 (87%)	18/22 (82%)	45/53 (85%)	4.354	1.493	2.223	8.528	< 0.001	
Tocilizumab	2/2	13/17 (76%)	15/19 (79%)	2.747	1.412	1.003	7.522	0.049	